Eleison Pharmaceuticals Inc. (ELSN)

Eleison Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)1,000,000
Net Income (ttm)-4.59M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ELSN

Eleison Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer. Our current portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). Each has received Orphan Drug Designation by the FDA, and glufosfamide and ILC have received Orphan Dr...

IndustryHealth Care
Founded2009
CEOEdwin J. Thomas
Employees2
Stock ExchangeNASDAQ
Ticker SymbolELSN
Full Company Profile

Financial Performance

In 2020, ELSN's revenue was $1,000,000, a decrease of -6.25% compared to the previous year's $1.07 million. Losses were -$5.80 million, 236.6% more than in 2019.

Financial Statements

News

Cancer biotech Eleison Pharmaceuticals files for a $42 million IPO

Eleison Pharmaceuticals, a Phase 3 biotech developing in-licensed therapies for cancer, filed on Monday with the SEC to raise up to $42 million in an initial public offering.

3 months ago - Renaissance Capital

Eleison Pharmaceuticals IPO Registration Document (S-1)

Eleison Pharmaceuticals has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC